We hypothesized that some people with COVID-19 may develop antibodies with catalytic activity because the RBD, since it binds ACE2, should have a partial negative image of ACE2, so some anti-RBD antibodies may have enough similarity to ACE2 to have proteolytic activity similar to ACE2, or perhaps other proteolytic enzymes due to substrate specificity spread seen with abzymes. The gene discussed is ACE2; the disease is COVID-19.